The prevalence of obesity, hypertension, and type 2 diabetes mellitus—in other words, the metabolic syndrome—is increasing in the United States. In this setting, it is important to understand the effects of antihypertensives on parameters of the metabolic syndrome in addition to glucose metabolism. Here the authors review pertinent clinical studies.
Get full access to this article
View all access options for this article.
References
1.
OngKL, CheungBMY, ManYB, LauCP, LamKSL. Prevalence, awareness, treatment and control of hypertension among United States adults 1999–2004. Hypertension, 2007; 49:69–75.
2.
CollinsR, PetoR, MacMahonS, HebertP, FiebachNH, EberleinKA, GodwinJ, QizilbashN, TaylorJO, HennekensCH. Blood pressure, stroke, and coronary heart disease part 2: short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet, 1990; 335:827–838.
3.
ChobanianAV, BakrisGL, BlackHR, CushmanWC, GreenLA, IzzoJLJr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Hypertension, 2003; 42:1206–1252.
4.
Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regiments on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet, 2003, 362:1527–1535
5.
SiegelD, HulleySB, BlackDM, CheitlinMD, SebastianA, SeeleyDG, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA, 1992; 267:1083–1089.
6.
MalikC, WongND, FranklinSS, KamathTV, L’ItalienGJ, PioJR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 2004; 110:1245–1250.
7.
ManriqueC, LastraG, Whaley-ConnellA, SowersJR. Hypertension and the cardiometabolic syndrome. J Clin Hypertens (Greenwich), 2005; 7:471–476.
8.
GrundySM, CleemanJI, DanielsSR, DonatoKA, EckelRH, FranklinBA, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005; 112:2735–2752.
9.
IshizakaN, IshizakaY, TodaE, HashimotoH, NagaiR, YamakadoM. Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals. Hypertens Res, 2005; 28:27–34.
10.
BenerA, SirieM, MusallamM, KhaderY, Al-HamaqA. Prevalence of Metabolic Syndrome According to Adult Treatment Panel III and International Diabetes Federation Criteria: A Population-Based Study. Metab Syndr Relat Disord, 2008; 7:221–228.
11.
FlegalKM, CarrollMD, OgdenCL, JohnsonCL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA, 2002; 288:1723–1727.
12.
MustA, SpadanoJ, CoakleyEH, FieldAE, ColdzG, DietzW. The disease burden associated with overweight and obesity. JAMA, 1999; 282:1523–1529.
13.
MokdadAH, FordES, BowmanBA, VinicorF, GilesWH. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA, 2003; 289:76–79.
14.
SharmaAM, EngeliS, PischonT. New developments in mechanisms of obesity-induced hypertension: Role of adipose tissue. Curr Hypertens Rep, 2001; 3:152–156.
15.
SiegelD, SalibaP, HaffnerS. Glucose and insulin levels during diuretic therapy in hypertensive men and their association with serum and intracellular potassium and magnesium. Hypertension, 1994; 23[part 1]:688–694.
16.
SowersJR, BakrisGL. Antihypertensive therapy and the risk of type 2 diabetes mellitus [editorial]. N Engl J Med, 2000; 342:969–970.
17.
ChenYD, SheuWH, SwislockiAL, ReavenGM. High density lipoprotein turnover in patients with hypertension. Hypertension, 1991; 17:386–393.
18.
FordES, GilesWH, DietzWH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA, 2002; 287:356–359.
19.
AppelLJ, MooreTJ, ObarzanekE, VollmerWM, SvetkeyLP, SacksFM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH collaborative Research Group. N Engl J Med, 1997; 336:1117–1124.
20.
AzadbakhtL, MirmiranP, EsmailzadehA, AziziT, AziziF. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care, 2005; 28:2823–2831.
21.
WheltonSP, ChinA, ExinX, HeJ. Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trial. Ann Intern Med, 2002; 136:493–503.
22.
PadwalR, LaupacisA. Antihypertensive therapy and incidence of type 2 diabetes: A systematic review. Diabetes Care, 2004; 27:247–255.
23.
ReavenGM, LithellH, LandsbergL. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med, 1996; 334:374–381.
24.
SwislockiAL, HoffmanBB, ReavenGM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens, 1989; 2:419–423.
25.
DunderK, LindL, ZetheliusB, BerglundL, LithellH. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: Population based cohort study. BMJ, 2003; 326:681.
26.
HsuehWA, LyonCJ, QuinonesMJ. Insulin resistance and the endothelium. Am J Med, 2004; 117:109–117.
27.
LindL, PollareT, BerneC, LithellH. Long-term metabolic effects of antihypertensive drugs. Am Heart J, 1994; 128:1177–1183.
28.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic; the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002; 88:2981–2997.
29.
SavagePJ, PresselSL, CurbJD, SchronEB, ApplegateWB, BlackHR, etal. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med, 1998; 158:741–751.
30.
KostisJB, WilsonAC, FreudenbergerRS, CosgroveNM, PresselSL, DavisBR; SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol, 2005; 95:29–35.
31.
TaylorEN, HuFB, CurhanGC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care, 2006; 29:1065–1070.
32.
SiegelD, MeierJ, MaasC, LopezJ, SwislockiALM, The effect of body mass index on fasting blood glucose after initiation of thiazide therapy in hypertensive patients. Am J Hypertens, 2008; 21:438–442.
33.
TweeddaleMG, OgilvieRI, RuedyJ. Antihypertensive and biochemical effects of chlorthalidone. Clin Pharmacol Ther, 1977; 22:519–527.
34.
CarlsenJE, KoberL., Torp-PedersenC, JohansenP. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ, 1990; 300:975–978.
PollareT, LithellH, BerneC. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med, 1989; 321:868–873.
40.
ReavenGM, ClinkingbeardC, JeppesenJ, MaheuxP, PeiD, FooteJ, et al. Comparison of the hemodynamic and metabolic effects of low dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens, 1995; 8:461–466.
41.
BramlageP, PittrowD, WittchenHU, KirchW, BoehlerS, LehnertH, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens, 2004; 17:904–910.
42.
ZappeDH, SowersJR, HsuehWA, HaffnerSM, DeedwaniaPC, FonsecaVA, et al. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich), 2008; 10:894–902.
43.
MartinsRD, AlvesRde S, SilvaGG, MartinsN, VasconcelosS, AssreuyA, et al. Antihypertensive treatment and its implications on lipoprotein metabolism of patients in care by a hypertension and diabetes program in Brazil. Acta Med Port. 2008; 21:567–574.
44.
LindholmLH, CarlbertB, SamuelssonO. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet, 2005; 366:1545–1553.
45.
BradleyHA, WiysongeCS, VolminkJA, MayosiBM, OpieLH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens, 2006; 24:2131–2141.
46.
KhanN, McAlisterFA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: A meta-analysis. CMAJ, 2006; 174:1737–1742.
47.
LithellH, PollareT, VessbyB. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press, 1992; 1:92–101.
48.
PollareT, LithellH, MörlinC, PräntareH, HvarfnerA, LjunghallS. Metabolic effects of diltiazem and atenolol: Results from a randomized, double-blind study with parallel groups. J Hypertens, 1989; 7:551–559.
49.
PollareT, LithellHO, SelinusI, BrnceC. Sensitivity to insulin during treatment with atenolol and metoprolol: A randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ, 1989; 298:1152–1157.
50.
SheuWHH, SwislockiAL, HoffmanB, ChenYDI, ReavenGM. Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension. Am J Hypertens, 1991; 4:199–205.
51.
GressTW, NietoFJ, ShaharE, WoofordMR, BrancatiFL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities study. N Engl J Med, 2000; 342:905–912.
52.
Cooper-DehoffR, CohenJD, BakrisGL, MesserliFH, ErdineS, HewkinAC, et al. INVEST Investigators. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (Findings from the International VErapamil SR-Trandolapril Study [INVEST]). Am J Cardiol, 2006; 98:890–894.
53.
HanssonL, LindholmLH, NiskanenL, LankeJ, HednerT, NiklasonA, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet, 1999; 353:611–616.
54.
DahlöfB, DevereuxRB, KjeldsenSE, JuliusS, BeeversG, de FaireU, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet, 2002; 359:995–1003.
55.
WicklmayrM, RettK, DietzeG, MehnertH. Effects of beta-blocking agents on insulin secretion and glucose disposal. Horm Metab Res Suppl, 1990; 22:29–33.
56.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ, 1998; 317:713–720.
57.
RossnerS, TaylorCL, ByingtonRP, FurbergCD. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ, 1990; 300:902–903.
LithellH, PollareT, BerneC, SaltinB. The metabolic and circulatory response to beta-blockade in hypertensive men is correlated to muscle capillary density. Blood Press, 1992; 1:20–26.
60.
SartoriC, ScherrerU. Insulin, nitric oxide and the sympathetic nervous system; at the crossroads of metabolic and cardiovascular regulation. J Hypertens, 1999; 17:1517–1525.
61.
JacobS, RettK, WicklmayrM, AgrawalB, AugustinHJ, DietzeGJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens, 1996; 14:489–494.
62.
GiuglianoD, AcamporaR, MarfellaR, De RosaN, ZiccardiP, RagoneR, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med, 1997; 126:955–959.
63.
BakrisGL, FonsecaV, AtholiRE, McGillJB, MesserliFH, PhillipsRA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension, a randomized controlled trial. JAMA, 2004; 292:2227–2236.
64.
BakrisGL, FonsecaV, KatholiRE, McGillJB, MesserliF, PhillipsRA, et al. GEMINI Investigators. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension, 2005; 46:1309–1315.
65.
Jacobs, HenriksenEJ. Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 2004; 6:690–696
66.
OlsenMH, WachtellK, BeeverG, DahlöfB, deSimone G, DevereuxRB, et al. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens, 2009; 27:567–574.
67.
BellDS, BakrisGL, McGillJB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab, 2009; 11:234–238
68.
PadwalR, MamdaniM, AlterDA, HuxJE, RothwellDM, TuK, et al. Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care, 2004; 27:2458–2463.
69.
Jandeleit-DahmKA, TikelisC, ReidCM, JohnstonCI, CooperME. Why blockage of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens, 2005; 23:463–473.
70.
YusufS, SleightP, PogueJ, BoschJ, DaviesR, DagenaisG. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000; 342:145–153.
71.
MouleSK, DentonRM. Multiple signaling pathways involved in the metabolic effects of insulin. Am J Cardiol, 1997; 80:41A–49A.
72.
NascimbenL, BothwellJH, DominguezDY, et al. Angiotensin II stimulates insulin-independent glucose uptake in hypertrophied rat hearts. Abstract. J Hypertens, 1997; 15,(Suppl 4):S84.
73.
SchorbW, PeelerTC, MadiganNN, ConradKM, BakerKM. Angiotensin II-induced protein tyrosine phosphorylation in neonatal rat cardiac fibroblasts. J Biol Chem., 1994; 269:19626–19632.
74.
WanY, KurosakiT, HuangXY. Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors. Nature, 1996; 380:541–544.
75.
SaadMJ, VellosoLA, CarvalhoCR. Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Biochem J, 1995; 310:741–744.
76.
MiatelloR, RislerN, GonzalezS, CastroC, RuttlerM, CruzadoM. Effects of enalapril on the vascular wall in an experimental model of syndrome X. Am J Hypertens, 2002; 15:872–878.
77.
KhanBV, SolaS, LautenWB, NatarajanR, HooperWC, MenonRG, et al. Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care, 2004; 27:1712–1715.
78.
FerderL, InserraF, Martinez-MaldonadoM. Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr Hypertens Rep, 2006; 8:191–198.
79.
ImanishiT, IkejimaH, TsujiokaH, KuroiA, KobayashiK, MuragakiY, MochizukiS, GotoM, YoshidaK, AkasakaT. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension, 2008; 51:734–741.
80.
MitrovicV, KleinHH, KrekelN, KreuzerJ, FichtlschererS, SchirmerA, PaarWD, HammCW. Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol, 2005; 94:336–342.
81.
BaeJH, RihalCS, EdwardsBS, KushwahaSS, MathewV, PrasadA, HolmesDRJr, LermanA. Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. Transplantation, 2006; 82:1108–1111.
82.
KrysiakR, Okopien´B. Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep, 2008; 60:514–523.
83.
PasiniAF, GarbinU, NavaMC, StranieriC, PellegriniM, BocciolettiV, LuchettaML, FabrizziP, LoCascio V, CominaciniL. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens, 2007; 20:443–450.
84.
KurtzTW, PravenecM. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system. J Hypertens, 2004; 22:2253–2261.
85.
KurtzTW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol, 2005; 42,(Suppl 1):S9–S16.
86.
KaragiannisA, MikhailidisDP, AthyrosVG, KakafikaAI, TziomalosK, LiberopoulosEN, FlorentinM, ElisafM. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: Are all the angiotensin receptor blockers equal?. Expert Opin Ther Targets, 2007; 11:191–205.
87.
BenndorfRA, RudolphT, AppelD, SchwedhelmE, MaasR, SchulzeF, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism, 2006; 55:1159–1164.
88.
NegroR, HassanH. The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. J Renin Angiotensin Aldosterone Syst, 2006; 7:243–246.
89.
ChujoD, YagiK, AsanoA, MuramotoH, SakaiS, OhnishiA, Shintaku-KubotaM, MabuchiH, YamagishiM, KobayashiJ. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res, 2007; 30:1205–1210.
90.
MakitaS, AbikoA, NaganumaY, MoriaiY, NakamuraM. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism, 2008; 57:1473–1478.
91.
KaragiannisA, MikhailidisDP, AthyrosVG, KakafikaAI, TziomalosK, LiberopoulosEN, et al. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opin Ther Targets, 2007; 11:191–205.
92.
O’BrienE, BartonJ, NussbergerJ, MulcahyD, JensenC, DickerP, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension, 2007; 49:276–284.
NussbergerJ, AubertJF, BouzoureneK, PellegrinM, HayozD, MazzolaiL. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension, 2008; 51:1306–1311.
95.
TrostBN, WeidmannP. Effects of calcium antagonists on diabetic subjects: A review. J Hypertens Suppl, 1987; 5:S81–S104.
96.
HoustonMC. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J, 1988; 115:640–656.
97.
RamsayLE, YeoWW, JacksonPR. Influence of diuretics, calcium antagonists, and alpha-blockers on insulin sensitivity and glucose tolerance in hypertensive patients. J Cardiovasc Pharmacol, 1992; 20,(Suppl 11):S49-S53; discussion S53-S54.
98.
RussellRP. Side effects of calcium channel blockers. Hypertension, 1988; 11:II42–II44.
99.
LindL, BerneC, PollareT, LithellH. Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. J Hum Hypertens, 1995; 9:137–141.
100.
ZhangR, ThakurV, MorseS, ReisinE. Renal and cardiovascular considerations for the nonpharmacological and pharmacological therapies of obesity-hypertension. J Hum Hypertens, 2002; 16:819–827.
101.
SheuWH, SwislockiAL, HoffmanB, ChenYD, ReavenGM. Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension. Am J Hypertens, 1991; 4:199–205.
102.
NathanS, PepineCJ, BakrisGL. Calcium antagonists: Effects on cardio-renal risk in hypertensive patients. Hypertension. 2005; 46:637–642.
103.
NakamuraT, InoueT, SuzukiT, KawagoeY, UedaY, KoideH, NodeK. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res, 2008; 31:841–850.
104.
JuliusS, KjeldsenSE, WeberM, BrunnerHR, EkmanS, HanssonL, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine; the VALUE randomised trial. Lancet, 2004; 363:2022–2031.
105.
FarahR, Shurtz-SwirskiR. The combined effect of calcium channel blocker Lercanidipine and antioxidants on low-grade systemic inflammation parameters in essential hypertension patients. Minerva Cardioangiol, 2008; 56:467–476.
106.
FogariR, PretiP, ZoppiA, LazzariP, CorradiL, FogariE, CiccarelliL, DerosaG. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol, 2006; 62:817–822.
107.
Martín-VenturaJL, Muñoz-GarciaB, Blanco-ColioLM, Martín-ConejeroA, Madrigal-MatuteJ, VegaM, OrtegaL, SerranoJ, EgidoJ. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int Suppl, 2008; 111:S71–S74.
108.
MudaP, KampusP, TeesaluR, ZilmerK, RistimäeT, FischerK, ZilmerM. Effects of amlodipine and candesartan on oxidized LDL level in patients with mild to moderate essential hypertension. Blood Press, 2006; 15:313–318.
109.
SwislockiAL, HoffmanBB, SheuWH, ChenYD, ReavenGM. Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med, 1989; 86,(1B):14–18.
110.
PollareT, LithellH, SelinusI, BerneC. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia, 1988; 31:415–420.
111.
SheuWH, SwislockiAL, HoffmanBB, ReavenGM, ChenYD. Effect of prazosin treatment on HDL kinetics in patients with hypertension. Am J Hypertens, 1990; 3:761–768.
112.
FerrariP, RosmanJ, NeunerN, ShawS, RiesenW, WeidmannP. Postsynaptic alpha 1-blockade with terazosin does not modify insulin sensitivity in nonobese normotensive subjects. J Cardiovasc Pharmacol, 1991; 18:106–110.
113.
AkbayE, BozluM, DorukE, AkbayE, CayanS, UlusoyE. Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia. Urol Int, 2001; 67:156–159.
114.
InukaiT, InukaiY, MatsutomoR, OkumuraK, TakanashiK, TakebayashiK, TayamaK, AsoY, TakemuraY. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism. J Int Med Res, 2004; 32:206–213.
115.
ShionoiriH, AshinoK, YamanakaK, ShindoK, HirotoS, AritaT. Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance. Clin Ther, 1997; 19:527–536.
116.
UeshibaH, MiyachiY. Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res, 2003; 35:532–536.
117.
TamasawaN, MatsuiJ, OgawaY, GotohT, HinataT, MurakamiH, ZhiGJ, SudaT. Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension. J Diabetes Complications, 2000; 14:135–139.
118.
DerosaG, CiceroAF, D’AngeloA, RagonesiPD, CiccarelliL, FogariE, SalvadeoSA, FerrariI, GravinaA, FassiR, FogariR. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. Clin Drug Investig, 2006; 26:529–539.
119.
PessinaAC, CiccarielloL, PerroneF, StoicoV, GussoniG, ScottiA, MuggeoM. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis, 2006; 16:137–147.
120.
HobbsFR, KhanT, CollinsB. Doxazosin versus bendrofluazide: A comparison of the metabolic effects in British South Asians with hypertension. Br J Gen Pract, 2005; 55:437–443.
121.
RabkinSW, HuffMW, NewmanC, SimD, CarruthersSG. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: The Alpha Beta Canada Study. Hypertension. 1994; 24:241–248.
SwislockiAL, VestalRE, ReavenGM, HoffmanBB. Acute metabolic effects of clonidine and adenosine in man. Horm Metab Res, 1993; 25:90–95.
125.
PrichardBN, GrahamBR. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. Drugs Aging, 2000; 17:133–159.
126.
AnichkovDA, ShostakNA, SchastnayaOV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin, 2005; 21:113–119.
127.
HanssonL, ZanchettiA, CarruthersSG, DahlöfB, ElmfeldtD, JuliusS, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomize trial. HOT Study Group. Lancet, 1998; 351:1755–1762.
128.
Tight blood pressure control and risk of macrovascular and microvascular complication in yype 2 diabetes: UKPDS38. UK Prospective Diabetes Study Group (no authors listed). BMJ, 1998; 317:703–713
129.
StaessenJA, FagardR, ThijsL, CelisH, ArabidzeGG, BirkenhägerWH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (syst-Eur) Trial Investigator. Lancet, 1997; 350:757–764.
130.
SHEP Cooperative Research Group. 1991. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program. JAMA, 1991; 265:3255–3264.
131.
SowersJR, HaffnerS. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension, 2002; 40:781–788.
132.
SowersJR. Treatment of hypertension in patients with diabetes. Hypertension, 2004; 164:1850–1857.
133.
NinomiyaJK, L’ItalienG, CriquiMH, WhyteJL, GamstA, ChenRS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation, 2004; 109:42–46.
134.
WilsonPW, KannelWB, SilbershatzH, D’AgostinoRB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med, 1999; 159:1104–1109.
135.
IsomaaB, AlmgrenP, TuomiT, ForsénB, LahtiK, NissénM, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001; 24:683–689.
136.
SternMP, WilliamsK, González-VillalpandoC, HuntKJ, HaffnerSM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?. Diabetes Care, 2004; 27:2676–2681.
137.
VerdecchiaP, ReboldiG, AngeliF, BorgioniC, GattobigioR, FilippucciL, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension, 2004; 43:963–969.
